The pandemic made Big Pharma even richer than before as vaccines and therapeutics splashed onto the market to the tune of billions of dollars. In the sophomore year of the pandemic, a boom in biotech interest fueled a rise in VC funding and a preclinical IPO flurry.
But the startup...
